Topical Corticosteroid Phobia and Personalized Behavioral Intervention (BERANI) Among Parents of Children With Atopic Dermatitis: A Multicenter RCT in Indonesia
Prevalence of Topical Corticosteroid Phobia and the Effectiveness of Personalized Behavioral Intervention (BERANI) Among Parents of Children With Atopic Dermatitis: A Multicenter Randomized Controlled Trial in Indonesia
The goal of this clinical trial is to understand the prevalence of topical corticosteroid phobia and to identify if personalized behavior intervention method can reduce the score of topical corticosteroid phobia among parents or caregivers of children with atopic dermatitis. The aims of the study are:
- to describe the prevalence of topical corticosteroid phobia in Indonesia
- to identify risk factor of topical corticosteroid phobia among parents of children with atopic dermatitis
- to evaluate if the intervention of BERANI method will reduce the score of topical corticosteroid phobia
- to assess the impact of intervention to the compliance and clinical outcome
Researchers will compare BERANI method to a standard care to see if BERANI method will reduce the score of topical corticosteroid phobia.
Participants will:
- fill a questionnaire and undergo physical examination for assessing the severity of atopic dermatitis
- get an audiovisual education or standard care education during the first visit based on randomization
- return in 14 days to fill a questionnaire and undergo physical examination.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Tuntas Rayinda, MD, PhD
- 電話番号:+62 (274) 560700
- メール:tuntas.rayinda@ugm.ac.id
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Parents or primary caregivers of pediatric patients (aged ≤18 years) with atopic dermatitis.
- Patients currently receiving or scheduled to receive topical corticosteroid therapy.
- Willingness to participate in the study.
Exclusion Criteria:
- Cognitive or psychiatric impairments that may hinder the educational process.
- Lack of access to WhatsApp for follow-up communication.
- Participation in a similar study within the past 6 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:BERANI
BERANI is a personalized behavior intervention to manage the topical corticosteroid phobia among parents of children with atopic dermatitis. BERANI stands for: B (Brief screening); E (Express concerns); R (Reassure & rectify); A (Audiovisual education); N (Navigate understanding); I (Intensify follow-up) |
BERANI is a personalized behavior intervention to manage the topical corticosteroid phobia among parents of children with atopic dermatitis. BERANI stands for:
|
|
介入なし:Standard Care
Patient will receive a standard education related to topical corticosteroid use for atopic dermatitis |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Topical Corticosteroid Phobia Score
時間枠:From enrollment to the end of intervention at 2 weeks
|
The topical corticosteroid phobia score will be assessed using TOPICOP instrument in Bahasa Indonesia. |
From enrollment to the end of intervention at 2 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Compliance of Topical Corticosteroid Use for Atopic Dermatitis
時間枠:From enrollment to the end of intervention at 2 weeks
|
Compliance of topical corticosteroid use will be assessed using 12-item Medication Adherence Scale (MAS) in Bahasa Indonesia. |
From enrollment to the end of intervention at 2 weeks
|
|
Disease Severity of Atopic Dermatitis
時間枠:From enrollment to the end of intervention at 2 weeks
|
The disease severity of atopic dermatitis will be assessed using EASI score. |
From enrollment to the end of intervention at 2 weeks
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Moret L, Anthoine E, Aubert-Wastiaux H, Le Rhun A, Leux C, Mazereeuw-Hautier J, Stalder JF, Barbarot S. TOPICOP(c): a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013 Oct 16;8(10):e76493. doi: 10.1371/journal.pone.0076493. eCollection 2013.
- Kelompok Studi Dermatologi Anak Indonesia. Data morbiditas Kelompok Studi Dermatologi Anak Indonesia 2024.
- Kenley H, Gunawan S. Gambaran corticophobia pasien psoriasis di Indonesia: studi berbasis TOPICOP. Damianus J Med. 2024;23(3):206-215.
- Lee JY, Her Y, Kim CW, Kim SS. Topical Corticosteroid Phobia among Parents of Children with Atopic Eczema in Korea. Ann Dermatol. 2015 Oct;27(5):499-506. doi: 10.5021/ad.2015.27.5.499. Epub 2015 Oct 2.
- Albogami MF, AlJomaie MS, Almarri SS, Al-Malki S, Tamur S, Aljaid M, Khayat A, Alzahrani A. Topical Corticosteroid Phobia Among Parents of Children with Atopic Dermatitis (Eczema)- A Cross-Sectional Study. Patient Prefer Adherence. 2023 Nov 2;17:2761-2772. doi: 10.2147/PPA.S431719. eCollection 2023.
- Contento M, Cline A, Russo M. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. Am J Clin Dermatol. 2021 Nov;22(6):837-851. doi: 10.1007/s40257-021-00623-6. Epub 2021 Jul 21.
- Starbek Zorko M, Bukovec V, Fantulin T. Topical Corticosteroid Phobia in Childhood Atopic Dermatitis: A Study Using the TOPICOP Score. Dermatol Res Pract. 2026 Mar 6;2026:7996688. doi: 10.1155/drp/7996688. eCollection 2026.
- Davis DMR, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2026 Jul;95(1):121.e1-121.e26. doi: 10.1016/j.jaad.2026.02.113. Epub 2026 Apr 7.
- Ueno H, Yamazaki Y, Yonekura Y, Park MJ, Ishikawa H, Kiuchi T. Reliability and validity of a 12-item medication adherence scale for patients with chronic disease in Japan. BMC Health Serv Res. 2018 Jul 31;18(1):592. doi: 10.1186/s12913-018-3380-7.
- Promthes T, Techasatian L, Salee-Or S, Uppala R, Sitthikarnkha P, Saengnipanthkul S, Sirikarn P, Kosalaraksa P. Topical corticosteroid phobia among caregivers: a study in atopic and nonatopic dermatitis children by using the TOPICOP score. Skin Health Dis. 2025 Jul 25;5(5):372-377. doi: 10.1093/skinhd/vzaf056. eCollection 2025 Oct.
- Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. J Allergy Clin Immunol. 2025 Apr;155(4):1124-1132. doi: 10.1016/j.jaci.2025.01.013. Epub 2025 Jan 22.
- Lee DG, Gui XY, Mukovozov I, Fleming P, Lynde C. Sleep Disturbances in Children With Atopic Dermatitis: A Scoping Review. J Cutan Med Surg. 2023 Mar-Apr;27(2):157-164. doi: 10.1177/12034754231159337. Epub 2023 Mar 7.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- KE/1654/10/2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。